An interventional study of NCM-Plus in MDR-TB and HIV, sponsored by Johns Hopkins University. Completed at 15 sites in South Africa. Open to participants aged 13 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by Johns Hopkins University · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies in Tuberculosis, Multidrug-Resistant with a site in South Africa — 7 open to participants now, 8 under way, 3 of them phase 3. Tuberculosis, Multidrug-Resistant · South Africa.
Among the 46 studies in Tuberculosis, Multidrug-Resistant with a site in South Africa, this one is the 3rd largest by enrollment of the 37 interventional ones that give a count, is one of 4 that started in 2014, is one of 8 with no phase, and was the 9th registered.
132 studies on the registry are indexed under Tuberculosis, Multidrug-Resistant; 25 are open to participants now.
Browse Tuberculosis, Multidrug-Resistant studies →7 of the 46 studies in Tuberculosis, Multidrug-Resistant with a site in South Africa are open now. Recruiting first, the newest first:
Albert Einstein College of Medicine · Sites in South Africa
Ages 18+
Otsuka Pharmaceutical Development & Commercialization, Inc. · Sites in South Africa, China, Georgia and 7 more countries
Ages 14+
University of California, San Francisco · Sites in South Africa
Johns Hopkins University · Sites in South Africa
Ages 18+
Columbia University · Sites in South Africa
Ages 18+ · Healthy volunteers
A study can be open while its sites in South Africa have not opened yet or have stopped. Only those recruiting at a site in South Africa →
Of the 20 Tuberculosis, Multidrug-Resistant studies recruiting now, 12 (60%) set no upper age limit and 7 (35%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.
This study: 13 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 16 · Phase 3 16 · Phase 4 1
First in 2007; this study’s year is marked. 4 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,844 is above the median of 194 across 88 interventional studies indexed under Tuberculosis, Multidrug-Resistant.
Median enrollment 248 across the 37 interventional studies, 786 across the 9 observational. Of the 32 that completed or were terminated, 17 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 46 have an industry lead sponsor. The 10 most frequent:
Johns Hopkins University is the lead sponsor of 1,817 studies on the registry; 316 are open to participants now.
Of its 208 completed or terminated interventional studies of FDA-regulated products, 144 (69%) have results posted.
Johns Hopkins University has 2 studies filed under Tuberculosis, Multidrug-Resistant — fewer than ten, so there is no comparison to draw.
2 of the studies in Tuberculosis, Multidrug-Resistant with a site in South Africa that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05553236University of California, San FranciscoPragmatic Use of Next-generation Sequencing for Management of Drug-resistant Tuberculosis | 2027-01 |
| NCT05633056Columbia UniversityAn Adaptive Randomized Controlled Trial | 2027-04 |
Add all 2 to your calendar (.ics) → With an account.
Among the 46 studies in Tuberculosis, Multidrug-Resistant with a site in South Africa, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The researchers of this study are observing the treatment of multi-drug resistant Mycobacterium tuberculosis (MDR-TB) in South Africa. MDR-TB can not be treated with the usual TB drugs and needs to be treated with special drugs. The patients need to take these drugs for up to two years. Certain hospitals have already agreed to participate in this research project, half of the hospitals will be assigned a nurse case manager and the other half will not. The researchers are studying the benefits of having a nurse case manager to improve treatment response for patients with drug resistant TB. The researchers believe that nurse case management (NCM) in the intervention sites will increase MDR-TB cure and completion rates (i.e. treatment success) in comparison to usual care (UC), i.e. standardized programmatic management alone, in patients with and without HIV co-infection. To do this, the researchers will review the medical information collected at the hospital as part of the patient's treatment after obtaining the patient's permission.
Mycobacterium tuberculosis (TB) remains the leading cause of death among persons living with Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV/AIDS) in southern Africa. This syndemic places an overwhelming burden on healthcare workers and the health system. Drug-resistant TB remains a growing threat to public health despite advances in treatment and diagnosis over the past decade. South Africa has the world's highest rate of TB/HIV co-infection and ranks fourth worldwide for both multi-drug resistant (MDR) TB incidence and HIV prevalence. Treatment of MDR-TB, defined as resistance to isoniazid and rifampin, remains challenging and its treatment course complex. Success of second line treatment regimens is considerably less likely than first line treatment with significantly more adverse drug reactions (ADRs). Prospective cohort studies from South Africa report less than 50% treatment success (i.e. cure or completion) and significant differences in patients with and without HIV are noted. Differences in sex and gender as well as age are rarely evaluated. In addition to the management complexity and length of treatment, systems level factors such as access to care and healthcare capacity contribute to poorer treatment outcomes. Insufficient numbers of trained physicians capable and clinically competent to manage the challenges of integrated MDR-TB/HIV care are commonplace. These circumstances place a heavy burden on the most abundant healthcare resource in South Africa, the nurse. Nurses with proficiency in care models for both diseases are essential to improve treatment outcomes. The investigators experience dictates, however, that patients endure lengthy treatment with little assessment, support or guidance from nursing professionals due to a lack of training as well as lack of evidence-based interventions and delineated models of care for MDR-TB patients.
Nurse case management (NCM) models in which a registered nurse facilitates and coordinates treatment plans to ensure that timely, evidence-based care is given improves treatment outcomes. Presently, there is little evidence to describe such models in TB/HIV co-infected patients globally, and specifically less evidence for MDR-TB/HIV in sub-Saharan Africa. Many studies, however, have demonstrated substantial improvements in disease outcomes utilizing nurse case managers. Complex diseases such as heart failure, diabetes, HIV and drug susceptible TB are among these. Substantial gaps remain, however, in the investigators understanding of the impact of such interventions among co-infected patients, the influence of such models among different age groups or the cost-benefit in under resourced settings. Prior studies provide strong evidence that interventions must be multi-faceted and foster system level approaches to improve treatment outcomes (i.e. NCM patient-centered care services coupled with systems level approaches to care coordination). The Chronic Care Model identifies essential elements of a health care system that encourage high-quality chronic disease care in such a systems approach. These elements provide the conceptual model and implementation structure for the proposed NCM plus health systems strengthening (i.e. NCM-plus) intervention, a multi-faceted health systems and patient-centered intervention to improve MDR-TB/HIV treatment outcomes. The proposed 5-year cluster randomized trial, will evaluate the NCM-plus intervention on MDR-TB treatment outcomes in South Africa, the epicenter of the MDR-TB/HIV epidemic.
Primary Aim:
To determine the impact of a NCM model (i.e. NCM-Plus) on MDR-TB outcomes in patients with and without HIV co-infection in South Africa through a cluster randomized trial.
Hypothesis:
Nurse case management (NCM) in intervention sites will increase MDR-TB cure and completion rates (i.e. treatment success) in comparison to usual care (UC), i.e. standardized programmatic management alone, in patients with and without HIV co-infection.
Secondary Aims:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Center (Cluster Level)
Individual (Patient Level)
Exclusion Criteria (Individual Patient Level):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The researchers designed the NCM-Plus intervention by integrating the domains of the Chronic Care Model with added attention to linkage to care, building on evidence-based guidelines and the team's pilot findings. In the NCM bundle, the researchers provide extensive details on both proximal and distal outcome variables. Nurse case managers will be hired and trained to improve disease management for patients with MDR-TB and HIV. Specific measurable responsibilities will be implemented by each NCM at sites randomized to receive the intervention. The NCM-patient interaction will occur at the MDR-TB treatment inpatient or outpatient facility.
Other: NCM-Plus
Usual care is defined as standardized programmatic management of MDR-TB/HIV without care coordination. Nurses are present as part of the team, but with no special coordination role, leaving the MDR-TB physician solely responsible for treatment outcomes with little support. Physicians see patients weekly during the intensive phase and the patient receives basic daily nursing care without coordination of care, active monitoring of Adverse Drug Reactions (ADR)s or HIV care integration. This care transitions to monthly visits with the physician in the continuation phase, again with very little nursing involvement in care coordination.
The NCM will follow the domains of the chronic care model by: 1. Assuring effective, efficient clinical care and self-management support 2. Promoting clinical care consistent with scientific evidence and patient preferences 3. Organizing data to facilitate efficient, effective care 4. Empowering and preparing patients to manage their health and health-care needs 5. Mobilizing community resources to meet the needs of patients
Patients Who Experience Successful Treatment Outcomes
Patients who experience successful treatment outcomes
Time frame: 36 months
Patients Who Experience Successful Treatment Outcomes Based on HIV Co-infection
Multivariate Analysis using binomial or Poisson-based GEE models
Time frame: 36 months
Patients Who Experience Successful Treatment Outcomes Based on Sex and Gender
Multivariate Analysis using binomial or Poisson-based GEE models
Time frame: 36 months
Patients Who Experience Successful Treatment Outcomes Based on Age
Multivariate Analysis using binomial or Poisson-based GEE models
Time frame: 36 months
Recruitment took place from October 2014 - September 2019 in 10 MDR- TB hospitals, 6 were in KwaZulu-Natal in the districts of eThekwini, Ugu, uMgungundlovu, uMkhanyakude, and Harry Gwala. The remaining 4 were in the Eastern Cape in the districts of Nelson Mandela, Sara Baartman, and Buffalo City.
| Milestone | Standard/Usual Care | NCM Plus Intervention |
|---|---|---|
| Started | 1389 | 1455 |
| Completed | 1041 | 1093 |
| Not completed | 348 | 362 |
| Withdrew: Baseline dst result pre-xdr/xdr | 152 | 225 |
| Withdrew: Baseline dst result ds-tb | 27 | 56 |
| Withdrew: Inha/katg mutation | 3 | 4 |
| Withdrew: Transferred out to another facility | 130 | 59 |
| Withdrew: Withdrawal for any other reason | 36 | 18 |
Patients who experience successful treatment outcomes
| Participants | Standard/Usual Care | NCM Plus Intervention |
|---|---|---|
| Patients Who Experience Successful Treatment Outcomes | 645 | 706 |
Multivariate Analysis using binomial or Poisson-based GEE models
| Participants | Standard/Usual Care | NCM Plus Intervention |
|---|---|---|
| Patients Who Experience Successful Treatment Outcomes Based on HIV Co-infection | 459 | 531 |
Multivariate Analysis using binomial or Poisson-based GEE models
| Participants | Standard/Usual Care | NCM Plus Intervention |
|---|---|---|
| Male | 353 | 401 |
| Female | 292 | 305 |
Multivariate Analysis using binomial or Poisson-based GEE models
| Participants | Standard/Usual Care | NCM Plus Intervention |
|---|---|---|
| 18 -24 | 106 | 92 |
| 25 - 34 | 219 | 223 |
| 35 - 44 | 178 | 213 |
| 45 - 54 | 98 | 115 |
| 55 - 64 | 35 | 50 |
| 65 - 74 | 8 | 9 |
| 75 - 84 | 1 | 2 |
| 85 - 94 | 0 | 2 |
Collected over Enrollment to Treatment Completion, up to 24 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Standard/Usual Care | 136/1,389 (9.8%) | 136/1,389 (9.8%) | 0/1,389 (0%) |
| NCM Plus Intervention | 156/1,455 (10.7%) | 156/1,455 (10.7%) | 0/1,455 (0%) |
| Event | Standard/Usual Care | NCM Plus Intervention |
|---|---|---|
| DeathGeneral disorders | 136/1389 | 156/1455 |
Participants with data collected
| Age, Continuous(Years) | Standard/Usual Care | NCM Plus Intervention | Total |
|---|---|---|---|
| Mean | 36.5 ± 12.0 | 38.2 ± 12.4 | 37.4 ± 12.2 |
| Sex: Female, Male(Participants) | Standard/Usual Care | NCM Plus Intervention | Total |
|---|---|---|---|
| Female | 463 | 435 | 898 |
| Male | 578 | 658 | 1236 |
| Race and Ethnicity Not Collected(Participants) | Standard/Usual Care | NCM Plus Intervention | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Residential Area(Participants) | Standard/Usual Care | NCM Plus Intervention | Total |
|---|---|---|---|
| City/CBD/Suburb | 30 | 50 | 80 |
| Farm | 5 | 15 | 20 |
| Township | 225 | 540 | 765 |
| Rural Village | 776 | 479 | 1255 |
| Unknown | 5 | 9 | 14 |
| Housing Type(Participants) | Standard/Usual Care | NCM Plus Intervention | Total |
|---|---|---|---|
| House | 921 | 954 | 1875 |
| Flat | 26 | 27 | 53 |
| Informal/Shack | 64 | 96 | 160 |
| Homeless/Other | 30 | 16 | 46 |
| Highest Level of Education(Participants) | Standard/Usual Care | NCM Plus Intervention | Total |
|---|---|---|---|
| None/Less than Secondary | 771 | 790 | 1561 |
| Secondary School | 197 | 218 | 415 |
| Some Technical/College Training | 30 | 45 | 75 |
| Technical/College Completed | 43 | 40 | 83 |
| Employment Status(Participants) | Standard/Usual Care | NCM Plus Intervention | Total |
|---|---|---|---|
| Employed | 288 | 373 | 661 |
| Student | 83 | 59 | 142 |
| Unemployed | 635 | 615 | 1250 |
| Retired/Disabled | 32 | 37 | 69 |
| Unknown | 3 | 9 | 12 |
| Marital Status(Participants) | Standard/Usual Care | NCM Plus Intervention | Total |
|---|---|---|---|
| Married | 104 | 148 | 252 |
| Partnered/In a Relationship | 354 | 182 | 536 |
| Separated/Widowed | 67 | 30 | 97 |
| Single | 510 | 722 | 1232 |
| Unknown | 6 | 11 | 17 |
21 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2014 to primary completion in Mar 2021, 77 months.
Results were first posted in Oct 2026, 5 years 7 months after primary completion.
Completion moved once since we started tracking on Sep 25, 2026: Jul 2026 → Dec 2025, on Oct 6, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tuberculosis, Multidrug-Resistant →